ACHC vs LFST: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
LFST is the larger of the two ($5.55B market cap): the incumbent the market prices for continued execution (33.87x forward earnings, beta 1.30). ACHC is the smaller challenger ($3.57B), cheaper on forward earnings (18.83x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
ACHC vs LFST: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ACHC | LFST | What it tells you |
|---|---|---|---|
| Market cap | $3.57B | $5.55B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 18.83 | 33.87 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.63 | 1.30 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 95% of range | 89% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.72 | 3.72 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: ACHC is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how ACHC and LFST affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ACHC and LFST share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ACHC and LFST exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Acadia Healthcare (ACHC) do?
Acadia Healthcare (NASDAQ: ACHC) is the leading pure-play behavioral healthcare provider in the United States, operating roughly 277 facilities with more than 12,500 licensed beds across about 40 states and Puerto Rico as of the end of 2025. Its business spans four service lines: acute inpatient psychiatric hospitals (its largest and fastest-growing segment), specialty treatment facilities, comprehensive treatment centers for opioid-use disorder, and residential treatment centers. Revenue is heavily tied to government payors, with Medicaid at roughly 58 percent, commercial at about 25 percent, and Medicare near 14 percent, and no single facility contributing more than about 4 percent of total revenue.
What does LifeStance Health Group (LFST) do?
LifeStance Health Group runs outpatient mental healthcare at national scale. Founded in 2017 and public since June 2021, the company employs licensed therapists, psychologists, psychiatrists and psychiatric nurse practitioners through its subsidiaries and supported practices, then routes patients to them through in-network insurance relationships. Care is delivered both in person and virtually, from more than ~550 centers spread across ~33 states, and volume reached roughly ~2.6 million patient visits in the second quarter of 2026 alone. Unlike cash-pay teletherapy apps, LifeStance is built around commercial insurance: about ~88% of revenue comes from commercial payors, ~7% from government programs and ~4% from self-pay, which means reimbursement rates negotiated with health plans, not consumer subscription pricing, set the revenue line.
ACHC vs LFST: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- ACHC drivers: Structural demand for behavioral health; Bed expansion and de novo growth.
- LFST drivers: Clinician headcount plus productivity, compounding together; Operating leverage on a largely fixed center and corporate base.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Legal and regulatory exposure is the defining risk. For LFST, payor concentration is the sharpest exposure: two commercial insurers each represented roughly ~14% to ~15% of revenue, so a single unfavorable contract renegotiation or a reimbursement policy shift can compress the rate per visit that drives margin expansion.
ACHC or LFST: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ACHC if you believe its drivers more; LFST if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ACHC and LFST guides.
ACHC vs LFST: the full fundamentals
ACHC. Acadia closed at ~$30.52 on October 16, 2026, up ~114% year to date after the stock rebounded from a 52-week low near $11.43. It trades at about 16.5x forward EPS and ~10.3x EV/EBITDA, with analysts' mean target near $33.79 across 14 firms, so the market is still discounting legal and reimbursement uncertainty. Reported earnings remain depressed by the late-2025 impairment, legal and interest costs even as adjusted metrics grow.
LFST. Pricing reflects the inflection rather than the trailing profit: the shares are up ~72% in 2026, yet forward earnings estimates (~$0.36 for 2026, ~$0.43 for 2027) put the multiple near ~28x rather than the ~92x trailing GAAP figure, and the gap is mostly stock compensation, amortization and litigation costs. Against full-year 2026 adjusted EBITDA guidance of ~$215M to ~$235M, enterprise value works out to roughly ~21x the midpoint. Cash of ~$226M against ~$276M of term loan principal leaves the balance sheet close to neutral, and analysts' mean target sits near ~$14.40 with a buy consensus.
Headline figures (approximate, October 2026): ACHC shows revenue (ttm) ~$3.37B (Q2 2026 ~$866M), 2026 revenue guidance (spring) ~$3.37B to $3.45B, q2 2026 adj. eps ~$0.38 (vs ~$0.35 est.), net income (ttm) ~-$1.13B (late-2025 impairment); LFST shows revenue (ttm) ~$1.58B (Q2 2026 +26% YoY), net income (ttm) ~$51M, or ~$0.13 per share, gross / operating margin ~34% / ~7%, free cash flow (ttm) ~$172M.
The bottom line: ACHC vs LFST
ACHC and LFST are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ACHC and LFST exposure against your real portfolio. It is not an investment adviser.
Wondering how ACHC or LFST fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Acadia Healthcare
Ask Walnut's AI anything about ACHC and see how it fits what you own.
FAQ
What is the difference between ACHC and LFST?
+
Acadia Healthcare (NASDAQ: ACHC) is the leading pure-play behavioral healthcare provider in the United States, operating roughly 277 facilities with more than 12,500 licensed beds across about 40 states and Puerto Rico as of the end of 2025. LifeStance Health Group runs outpatient mental healthcare at national scale. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ACHC or LFST the better stock?
+
Neither is universally better. LFST is the larger incumbent; ACHC is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ACHC or LFST?
+
On forward P/E (as of November 2026), ACHC trades at 18.83x and LFST at 33.87x, so ACHC is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ACHC and LFST?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ACHC vs LFST?
+
ACHC: Legal and regulatory exposure is the defining risk. Acadia agreed to pay $179 million to settle a securities class action tied to prior disclosures, faces a September 2024 DOJ Criminal Division grand jury subpoena related to its acute admissions, length of stay, and billing practices, and disclosed a sharp rise in patient-related litigation expense (roughly $116 million projected for 2025 versus $54 million in 2024). A 2024 New York Times investigation alleged patients were improperly detained, and a May 2026 California jury awarded $105 million in a retaliatory-termination case. The company also carries meaningful leverage, with total debt around $2.6 billion against ~$171 million of cash at June 30, 2026, and took a large goodwill impairment in late 2025 that left trailing twelve-month net income at about -$1.1 billion. Free cash flow over the trailing year was negative (about -$105 million) as capital spending on new beds outran operating cash flow of ~$211 million. Heavy Medicaid and Medicare reliance leaves it exposed to reimbursement-rate and policy changes. LFST: Payor concentration is the sharpest exposure: two commercial insurers each represented roughly ~14% to ~15% of revenue, so a single unfavorable contract renegotiation or a reimbursement policy shift can compress the rate per visit that drives margin expansion. Valuation leaves little cushion after a ~138% one-year run, with the stock near ~92 times trailing earnings, ~28 times forward earnings and ~37 times EV to EBITDA on a business whose GAAP net margin is about ~3%, meaning a growth deceleration toward the ~11% pace of 2025 would be poorly received. Legal and regulatory matters are ongoing rather than resolved: a privacy class action captioned Strong v. LifeStance Health Group, filed April 26, 2023 over the use of website pixel tracking technologies, is settling for roughly ~$3.0 million with a final approval hearing scheduled for October 2026 (the outcome was not yet reported in the sources reviewed for this October 16 update), and the June 2021 IPO drew a securities class action in 2022 that is no longer disclosed as a pending matter in the company's Legal Proceedings item. Healthcare providers of this scale also carry standing exposure to fraud and abuse statutes, retroactive payor audits and state licensure rules across all ~33 states of operation. Financial leverage is moderate but real, with roughly ~$276M of term loan principal outstanding at SOFR plus ~3.00% maturing in December 2029 under a net leverage covenant, and TPG and Summit Partners together still hold about ~35.4% of the shares, an overhang that can weigh on the stock whenever those holders trim. Insider selling is routine but visible: the chief technology officer sold 42,067 shares for about ~$541K in September 2026.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ACHC or LFST; figures are approximate and dated (as of November 2026). Verify current data before investing.